Provided by Tiger Trade Technology Pte. Ltd.

COMPASS Pathways plc

13.51
-0.2200-1.60%
Post-market: 13.48-0.0280-0.21%19:59 EDT
Volume:1.78M
Turnover:24.11M
Market Cap:1.86B
PE:-3.74
High:13.94
Open:13.80
Low:13.43
Close:13.73
52wk High:15.40
52wk Low:4.40
Shares:138.00M
Float Shares:107.00M
Volume Ratio:0.80
T/O Rate:1.66%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.6118
EPS(LYR):-3.0800
ROE:-319.07%
ROA:-29.08%
PB:22.06
PE(LYR):-4.39

Loading ...

BUZZ-Psychedelic drug developers rise after Trump signals regulatory support

Reuters
·
Apr 20

Compass Pathways commends White House order to speed psychedelic treatment access

Reuters
·
Apr 19

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments

THOMSON REUTERS
·
Apr 19

Compass Pathways Plc - Already Working With FDA on Rolling Submission for Comp360 in Treatment-Resistant Depression

THOMSON REUTERS
·
Apr 19

BUZZ-Psychedelic drug developers rise after CBS report Trump backs more research

Reuters
·
Apr 17

Compass Pathways publishes 2025 annual report

Reuters
·
Apr 16

Compass Pathways announces annual shareholder meeting

Reuters
·
Apr 16

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Nano-X, Travere

Reuters
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Bloom Energy, BlackRock, CoreWeave

Reuters
·
Apr 14

BUZZ-Compass Pathways rises as it launches US training grants for psilocybin care

Reuters
·
Apr 14

Compass Pathways Announces U.s Grant Program for the Creation of Post-Approval Comp360 Provider Training

THOMSON REUTERS
·
Apr 14

Compass Pathways to present at Needham Virtual Healthcare Conference fireside chat

Reuters
·
Apr 08

Compass Pathways grants 173,320 inducement equity awards to new hires under 2026 plan

Reuters
·
Apr 08

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 08

LifeSci Capital Keeps Their Buy Rating on COMPASS Pathways (CMPS)

TIPRANKS
·
Mar 28

Compass Pathways Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Mar 26

RBC Capital Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)

TIPRANKS
·
Mar 26

Compass Pathways price target lowered to $18 from $20 at Canaccord

TIPRANKS
·
Mar 26

Compass Pathways Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Mar 26

Oppenheimer Sticks to Their Buy Rating for COMPASS Pathways (CMPS)

TIPRANKS
·
Mar 26